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ABSTRACT 
Background: Increased visceral fat, dyslipidemia and increased markers of inflammation and 
coagulation  are  cardiovascular  risk  factors  commonly  encountered  in  obese  people  with 
metabolic syndrome. Previous studies have shown that ground Dichrostachys glomerata (DG), a 
spice used in Western Cameroon, can have beneficial effects on inflammation and various other 
cardiovascular disease risk factors. The purpose of the present study was to evaluate the effects 
of Dyglomera®, an aqueous extract of DG (standardized to NLT 10% polyphenols)   on certain 
anthropometric,  biochemical  (including  pro-inflammatory  and  pro-thrombotic  states)  and 
hemodynamic parameters in obese patients with metabolic syndrome.  
 
Methods: The study was an 8-week randomized, double-blind, placebo-controlled trial involving 
116 males and 202 females aged between 24 and 58 years. Participants were randomly divided 
into  two  groups:  treatment  and  placebo.  Capsules  containing  the  active  treatment  (200  mg 
Dyglomera®) or placebo (200 mg maize powder) were administered 30–60 minutes before lunch 
and  dinner  throughout  the  study  period.  Various  biochemical  (namely,  blood  glucose,  lipid 
profile,  pro-inflammatory  and  pro-thrombotic  markers),  anthropometric  and  hemodynamic 
parameters were measured at baseline and after 4 and 8 weeks of treatment.   Functional Foods in Health and Disease 2013; 3(11):416-427                                                          Page 417 of 427 
 
Results:  At  the  end  of  the  study,  the  Dyglomera®  group  showed  statistically  significant 
differences  in  all  16  parameters  compared  to  baseline  values.  Changes  in  BMI  and  waist 
circumference were accompanied by changes in biochemical parameters, with the exception of 
adiponectin  levels  which  were  not  correlated  to  waist  circumference  and  PAI-1  values.  The 
results  confirm  the  hypothesis  that  Dyglomera®,  the  aqueous  extract  of  DG,  has  anti-
inflammatory  properties,  and  is  effective  in  reducing  cardiovascular  disease  risk  factors 
associated with metabolic syndrome in obese human subjects. 
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1. INTRODUCTION 
Obesity and its related complications are generally referred to as metabolic syndrome (MetS) and 
its prevalence is increasing worldwide, with some countries experiencing as much as a three-fold 
increase in the last three decades [1]. Due to the fact that MetS is a multifactorial disorder 
involving genetic and environmental factors, its management remains a challenge to scientists 
worldwide. Even though obesity-related complications appear to be secondary to the condition 
itself,  some  of  the  accompanying  changes  are  life-threatening,  requiring  a  combination  of 
management  strategies  for  appropriate  control.  This  is  the  case  in  type  2  diabetes  mellitus, 
dyslipidemia, atherosclerosis, hypertension, oxidative stress, and inflammation. MetS comprises 
a clustering of atherosclerotic factors, including visceral obesity, dyslipidemia, and disturbed 
carbohydrate metabolism [2]. It is associated with pro-inflammatory and pro-thrombotic states, 
in which the role of increased visceral fat deposits is thought to be central. Abdominal obesity 
leads  to  alteration  of  the  normal  physiological  balance  of  adipokines,  insulin  resistance, 
endothelial dysfunction and a pro-atherogenic state [3,4]. In association with this, the presence of 
conventional cardiovascular risk factors such as hypertension results in a significantly elevated 
cardiometabolic  risk.  The  pathway  leading  to  MetS  involves  the  abnormal  production  of 
hormones and cytokines from the adipose tissue [3], namely, excessive production of IL-6, TNF-
α  and  the  prothrombotic  agent  plasminogen  activator  inhibitor  type  1  (PAI-1).    This  is 
accompanied  by  low  secretion  of  the  protective  adipocytokine  adiponectin,  a  molecule  that 
exerts anti-inflammatory, anti-atherogenic, and anti-diabetic effects, and whose production is 
down-regulated  in  obese  individuals  with  metabolic  syndrome  [3,5].  On  the  other  hand, 
overproduction of IL-6 by the adipose tissue in obesity induces hepatic (C-reactive protein) CRP 
synthesis, which promotes the onset of cardiovascular complications [6].  
The  management  of  disorders  clustered  in  this  syndrome  and  the  elucidation  of  the 
mechanisms involved in its development are of great interest for the benefit of health. While 
lifestyle  modification  through  dietary  intervention  and  exercise  have  had  limited  success  in 
treating these disorders, they have not stopped the increasing prevalence of MetS and may have 
low long-term sustainability.  Pharmacological therapy has therefore been proposed as an adjunct 
to diet and lifestyle changes to improve long-term weight loss [7]. The numerous synthetic drugs 
developed to combat obesity and metabolic syndrome have had only marginal success, due in Functional Foods in Health and Disease 2013; 3(11):416-427                                                          Page 418 of 427 
part to their accompanying adverse effects [8,9]. This has turned the focus of some researchers 
towards  nutraceuticals,  compounds  derived  from  foods  or  other  natural  products  that  are 
considered to be safer. Medicinal foods and herbal drugs are therefore widely prescribed, even 
when their biologically active compounds are unknown [10,11].
 
Dichrostachys glomerata (DG) (Forssk.). Chiov. is a deciduous tree found in Cameroon 
and  other  tropical  countries.  DG  produces  edible  fruits  and  seeds,  and  the  dried  fruits  are 
commonly used as a spice in a traditional soup of the Western provinces of Cameroon called 
“Nah poh”[12]. The hypotensive property of the plant was first reported more than four decades 
ago [13]. This plant has been shown to have antiviral, anti-infectious, [14] anti-inflammatory, 
and  analgesic  effects  in  rats  [15]  and  cicatrizing  effects  [16].  A  study  from  our  laboratory 
showed  that  DG  fruits  also  exhibit  in  vitro  and  in  vivo  antioxidant  activity  and  can  inhibit 
oxidation of low-density lipoproteins (LDL) [17]. A study of diabetic rats showed the ability of 
DG to reduce fasting blood glucose and glycosylated hemoglobin levels [18]. A recent study 
indicated that whole, ground  DG had a positive effect on cardiovascular risk factors associated 
with obesity and type 2 diabetes [19]. While these reports suggest that DG can have beneficial 
effects on health, the bioactive components of DG have not been well characterized. Toward this 
end  the  current  study  was  undertaken  to  evaluate  the  effects  of  an  aqueous  extract  of 
standardized DG on MetS markers in obese humans.   
 
2. METHODS AND MATERIALS   
2.1.  Test  material:  Dyglomera®,  an  aqueous  extract  of  DG  (standardized  to  NLT  10% 
polyphenols), was supplied by Gateway Health Alliances, Fairfield, California, USA.  They were 
supplied  as  200  mg  capsules.    Identical-looking  placebo  capsules  were  also  manufactured 
containing 200 mg of maize-based powder.  
 
2.2. Study population and intervention 
The  study  was  a  double-blind,  placebo-controlled  trial  lasting  8  weeks.  A  total  of  318 
participants (202 females and 116 males) were randomly selected from a pool of 1,360 obese 
subjects  previously  recruited  from  the  city  of  Yaounde  and  its  environs.  The  participants 
included males and non-pregnant/non-lactating females aged 24–58 years, with a BMI between 
30-40 kg/m
2. The NCEP ATP III criteria were used for the diagnosis of MetS, such that if any 
three of the following conditions were present in the same patient they were considered to have 
MetS: waist circumference > 102 cm in men and > 88 cm in women; triglycerides (TAG) ≥ 150 
mg/dL; high-density lipoprotein (HDL) < 40 mg/dL in men and < 50 mg/dL in women; fasting 
glucose ≥ 110 mg/dL and blood pressure ≥ 130/85 mm Hg (or use of antihypertensive agents) 
[20]. A physician examined participants to ascertain their eligibility for inclusion in the study. 
Participants were randomly divided into two groups, and were instructed to take 200 mg of either 
Dyglomera® or placebo 30-60 min before lunch or dinner throughout the study period.  They 
were asked to report any lapses in taking the pills.  Since the capsules were identical in size, 
shape, and appearance, neither the researchers nor participants knew which treatment was given. 
Participants were encouraged to maintain their prior lifestyle and dietary habits throughout the 
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2.3. Exclusion criteria  
Exclusion criteria included impaired kidney function, cardiac problems, serious hypertension 
(systolic and diastolic blood pressure above 180 mm Hg, and 110 mm Hg, respectively), need for 
daily insulin management, and enrollment in another clinical study within the past 6 months. 
Also excluded were volunteers with a history of drug or alcohol abuse, those on cholesterol-
lowering,  inflammation-reducing  and/or  other  medications  (e.g.,  steroids)  that  interfere  with 
blood clotting and wound repair, as well as participants with infections including HIV/AIDS or 
cancer. 
 
2.4. Approval and informed consent  
The study was approved by the local ethical committee (Approval No. 006/CNE/MP/07). The 
purpose, nature, and potential risks of the study were explained to all participants, who gave their 
written informed consent before participation. The study was done in full accordance with the 
ethical provisions of the World Medical Association Declaration of Helsinki (as amended by the 
52nd General Assembly, Edinburgh, Scotland, October 2000). 
 
2.5. Anthropometric measurements 
Various anthropometric parameters were measured at baseline and at biweekly follow-up visits 
for the 8 weeks of treatment. Height was measured with a Harpenden™ stadiometer (Cranlea & 
Company, Birmingham, UK), which measures height to the nearest 0.5 cm. Body weight and 
percentage  body  fat  were  assessed  using  a  Tanita
TM  BC-418  Segmental  Body  Composition 
Analyzer/Scale (Arlington Heights, Illinois, USA) that uses bioelectrical impedance analysis to 
compute body composition. BMI was calculated as the ratio of weight (kg) to height squared 
(m
2). Waist (average of narrowest and the widest parts of the trunk) and hip (widest point) 
circumferences were measured to the nearest 0.1 cm. The participants were asked to fast for 12 
hours and to wear light clothing for visits when measurements were taken. The participants were 
measured at approximately the same time of day and by the same technician across visits. 
 
2.6. Blood pressure 
As  with  the  anthropometric  measurements,  blood  pressure  was  recorded  at  baseline  and  at 
biweekly follow-up visits. Blood pressure was measured on the left arm after a 10-minute rest. 
Triplicate readings were taken over 5-minute intervals and the average was recorded. 
 
2.7. Sample collection 
At Week 4 and Week 8, blood samples (5 ml of blood) were collected after a 12-hour overnight 
fast. The plasma or serum obtained from each blood sample were split into multiple 500 µl 
aliquots and stored at -20 °C until needed.   
 
2.8. Analytical methods  
This study used the Trinder glucose activity test [21], which determines glucose in the blood 
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by the cholesterol oxidase method [22], while triglycerides were assayed following the method 
described  by  Bucolo  and  David  [23].  HDL  cholesterol  was  determined  using  a  heparin 
manganese  precipitation  of  Apo  B-containing  lipoproteins  [24],  and  LDL  cholesterol  was 
calculated using the Friedewald formula [25].  C-reactive protein was measured using an ELISA 
method (BioCheck™ hsC Reactive Protein ELISA kit, Foster City, CA USA). . Fasting insulin 
(mIU/l) was determined using the Medgenic immunoenzymetric assay by Biosource-Europe SA 
(Nivelles,  Belgium).  Insulin  sensitivity  was  assessed  by  the  homeostasis  assessment  model 
(HOMA-IR  [mmol/L  ×  mU/L]  =  (fasting  glucose  [mmol/L]  ×  fasting  insulin  [mU/L]/22.5). 
Fasting serum adiponectin was measured using the Linco RIA, and PAI-1 concentrations were 
assessed by  using an enzyme-linked immunosorbent  assay (Diagnostica Stago, Asnières-sur-
Seine, France). 
 
2.9. Statistical analysis 
The data were summarized (mean and standard error) for Week 0 (baseline), Week 4, and Week 
8 (final), and the intra-group variation and the data were analyzed using SPSS 16.0 for Windows 
(SPSS Inc., Chicago, IL, USA). Because the repeated measurements on each participant were 
correlated in nature (covariance), a mixedmodel approach was used to characterize variation 
between  patients  and  within  patients  because  it  is  a  flexible  tool  for  analyzing  repeated, 
longitudinal treatments. The interaction between time and intervention was tested at the 0.05 
level of significance. If the interaction was significant, comparisons were made between the 
treatment and placebo groups for each month. Between-treatment changes were tested using one-
way analysis of covariance (ANCOVA), adjusted for baseline values, with the initial value as a 
covariate. Bilateral correlations between variables were examined using Pearson’s correlation 
coefficients. P values less than 0.05 were considered to be statistically significant. 
 
3. RESULTS  
3.1. Baseline characteristics  A total of 297 individuals (154 in the Dyglomera® treatment group 
and 143 in the placebo group) out of 318 initial participants completed the study (21 participants 
dropped out of the study). The number of premature withdrawals was higher in the placebo 
group  than  in  the  Dyglomera®  group  (16  vs  5).  The  baseline  (T0)  anthropometric, 
hemodynamic, and metabolic characteristics of the two study groups are listed in Tables 1–4. 
Plasma  TAG,  total  cholesterol,  plasma  glucose,  insulin  resistance  (HOMA-IR),  CRP,  and 
circulating PAI-1 were slightly higher at T0, whereas HDL cholesterol and adiponectin were 
lower at T0 than normal values, which is reflective of the obese status of the patients in the 
study. The baseline characteristics across the two experimental groups were not significantly 
different.  
 
3.2. Anthropomorphic characteristics and blood pressure.   Table  1  shows  the  changes  in  the 
various anthropometric variables (body weight, BMI, waist and hip circumference, and percent 
body fat) over the 8-week trial period.  
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Table 1. Anthropometric effects of DG in obese subjects with metabolic syndrome 
 
Variable  Group  T0  T4  T8  Change from baseline      
(T8 - T0) (%) 
Weight (kg)  DG  99.26± 1.12  93.73± 1.07
a  88.12± 1.05
b  -11.15± 0.18 (-11.33)
† 
Placebo  98.69± 1.15  98.72± 1.12
  98.17± 1.11
  -0.53± 0.11 (-0.49)
 
BMI (kg/m
2)  DG  36.63± 0.25  34.59± 0.25
a  32.51±0.26
b  -4.13± 0.06 (-11.33)
† 
Placebo  36.02± 0.26  36.04± 0.26  35.84± 0.26  -0.18± 0.04 (-0.49) 
Waist (cm)  DG  106.20± 0.88  99.79± 0.98
b  95.48± 0.99
b  -10.72± 0.28
† (-10.23)
† 
Placebo  105.43± 1.00  105.49± 0.97
  104.65± 0.97
  -0.77± 0.08 (-0.70)
 
Hip (cm)  DG  127.37± 0.73  122.92± 0.75
a  118.34± 0.73
b  -9.03± 0.22 (-7.10)
† 
Placebo  126.52± 0.82  126.34± 0.85
  125.88± 0.84
  -0.64± 0.21 (-0.51)
 
Body fat (%)  DG  44.88± 0.58  42.32± 0.56
a  40.15± 0.55
b  -4.73± 0.11 (-10.68)
† 
Placebo  44.28± 0.61  44.37± 0.60
  44.08± 0.59
  -0.20± 0.10 (-0.37)
 
 
ap < 0.05 compared with placebo, adjusted for baseline 
bp < 0.001 compared with placebo, adjusted for baseline 
†p < 0.05 compared with baseline, intra-group analysis 
 
Compared to the placebo group, the Dyglomera® treatment group showed a significant average 
weight  reduction  of  11.15  kg  (-11.33%  of  total  body  weight)  (p  <  0.001)  after  8  weeks  of 
treatment with Dyglomera®. The amount of weight loss achieved in the current study using 
Dyglomera® was higher than that obtained with whole, ground DG in a previous study[19]. This 
reduction  in  weight  was  accompanied  by  a  loss  of  visceral  fat  as  measured  by  waist 
circumference (-10.23%). In general, changes to BMI, waist and hip circumferences, and body 
fat paralleled the loss in weight. Similarly, blood pressure also decreased significantly in the 
Dyglomera® treatment group compared with the placebo group (p < 0.001)  (Table 2).   
 
Table 2. Effects of DG on blood pressure in obese subjects with metabolic syndrome 
 
Variable  Group  T0  T4  T8  Change from baseline     
(T8 - T0) (%) 
SBP (mm Hg) 
DG  143.93± 0.48  122.51± 1.07
b   119.75± 0.92
b  -24.18± 1.00 (-16.69)
† 
Placebo  142.60± 0.54  142.92± 0.83
  144.29± 0.95
  1.69±0.83 (+1.22)
 
DBP (mm Hg) 
DG  93.43± 0.52  85.62± 0.6
b   82.25± 0.69
b   -11.18± 0.66 (-11.81)
† 
Placebo  93.29± 0.54  94.77± 0.61
  95.27± 0.68
  1.99± 0.47 (2.19)
 
 
ap < 0.05 compared with placebo, adjusted  for baseline 
bp < 0.001 compared with placebo, adjusted for baseline   
†p < 0.05 compared with baseline, intra-group analysis 
 
3.3. Blood parameters: As shown in Table 3, there were significant variations in the lipid profile 
from baseline to Week 8 of Dyglomera® treatment in TAG, TC, HDL and LDL concentrations.  
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Table 3. Effects of DG on blood glucose and lipid parameters in obese subjects with metabolic 
syndrome 
 
Variable  Group  T0  T4  T8  Change from baseline      
(T8 - T0) (%) 
Glucose 
(mg/dL) 
DG  110.25± 0.48  85.82± 0.82
a  79.55± 0.51
b  -30.70± 0.66 (-27.67)
 † 
Placebo  108.99± 0.74  110.54± 0.68
  111.75± 0.77
  2.76± 0.59 (+2.72) 
TAG 
(mg/dL) 
DG  151.92± 3.01  46.80± 2.48
a  44.01± 1.86
b  -105.12± 3.54(-69.49)
 † 
Placebo  150.79± 1.78
   156.11± 3.04
  151.77± 2.39
  0.98± 2.91 (+4.33)
 
TC 
(mg/dL) 
DG  219.57± 1.82  137.84± 2.73
b  122.76± 3.36
b  -96.82± 3.65 (-43.67)
 † 
Placebo  216.47± 3.26  217.91± 2.98
  216.35± 3.16
  -0.12± 1.88 (+0.63)
 
HDL 
(mg/dL) 
DG  37.68± 0.54  50.39± 1.58
a  58.23± 1.07
b  20.55± 0.84 (+55.52)
 † 
Placebo  27.24± 0.99  19.87± 1.09
  24.92± 1.13
  -2.32± 1.05 (+0.41)
 
LDL 
(mg/dL) 
DG  151.51± 1.96
   78.09± 3.02
a  76.27± 3.44
b  -75.23± 3.60 (-49.18)
 † 
Placebo  159.07± 3.26
   166.82± 3.12
   161.07±3.39
   2.00± 2.26
  (+1.61)
 
 
ap < 0.05 compared with placebo, adjusted for baseline 
bp < 0.001 compared with placebo, adjusted for baseline 
†p < 0.05 compared with baseline, intra-group analysis 
 
These variations were significant compared with the placebo group (p < 0.001). There was also a 
significant reduction of blood glucose by 27.67% in the Dyglomera® group from baseline to 
Week 8  (p < 0.001) (Table 3). As shown in  Table 4, the  Dyglomera® group demonstrated 
significant reductions in insulin and insulin resistance (HOMA-IR) respectively by 10.38% and 
35.11%,  CRP  by  17.16%,  PAI-1  by  39.61  %  in  response  to  the  weight  loss  during  the 
Dyglomera® supplementation from baseline to Week 8 (p < 0.001). Inverse to the change in 
body weight, adiponectin levels increased by 21.86% in the Dyglomera® group from baseline to 
Week 8. 
 
Table 4. Effects of DG on insulin resistance and circulating markers of inflammation and blood 
coagulation in obese subjects with metabolic syndrome 
 
Variable  Group  T0   T4  T8  Change from baseline (T8 
- T0) (%) 
Insulin (mIU/L)  DG  13.01± 0.15  12.27± 0.13
a  11.67± 0.15
a  -1.34± 0.10 (-10.38)
 † 
Placebo  13.80± 0.74  13.71± 0.17
  13.66± 0.19
  -0.15± 0.11 (-1.05) 
HOMA-IR 
(mmol/L×mU/L) 
DG  3.55± 0.04  2.60± 0.04
a  2.30± 0.03
a  -1.25± 0.03 (-35.11)
 † 
Placebo  3.71± 0.05  3.74± 0.05
  3.77± 0.06
  0.06± 0.04 (+1.65)
 
Adiponectin 
(µg/mL) 
DG  5.80± 0.11  6.51± 0.14
 a  7.08± 0.17
b  1.28± 0.10 (21.86)
 † 
Placebo  5.48± 0.15  5.51± 0.19
  5.54± 0.19
  0.05± 0.11 (+0.40)
 
CRP (mg/L)  DG  6.43± 0.14  5.80± 0.07
a  5.10± 0.11
b  -1.32± 0.14 (-17.16)
 † 
Placebo  6.12± 0.99  6.25± 0.21
  6.07± 0.21
  -0.05± 0.14 (-1.73)
 
PAI-1 (ng/L)  DG  32.58± 0.22  26.25± 0.34
a  19.81± 0.37
b  -12.77± 0.26 (-39.61)
 † 
Placebo  33.14± 0.26  32.39± 0.28
  32.31±0.28
  -0.83± 0.09 (-2.52)
 
 
ap < 0.05 compared with placebo, adjusted for baseline 
bp < 0.001 compared with placebo, adjusted for baseline 
†p < 0.05 compared with baseline, intra-group analysis Functional Foods in Health and Disease 2013; 3(11):416-427                                                          Page 423 of 427 
With  regard  to  lipid  profiles,  this  study  confirms  the  strong  hypolipidemic  effects  of 
Dyglomera® and suggests it could protect against MetS through reduced TC (mean = 96.82 
mg/dL  (-43.67%)),  reduced  LDL  (mean  =  75.23  mg/dL  (-49.18%)),  reduced  TAG  (mean  = 
105.12 mg/dL (-69.49%)) and increased HDL (mean = 20.55 mg/dL (+55.52%)).  
  
3.4. Correlation of select anthropometric changes with metabolic parameters and adipocytokines 
before and after weight loss.   
Pearson correlations between outcome variables are presented in Table 5 and they reveal that the 
change  in  BMI  was  significantly  associated  with  changes  in  insulin,  HDL,  LDL,  CRP, 
adiponectin, insulin and  PAI-1 levels (p <0.01). Similarly, waist circumference reduction was 
significantly associated with the all the above mentioned parameters except adiponectin. While 
there  was  no  significant  correlation  between  the  adipocytokines  adiponectin  and  PAI-1, 
increased HDL was positively correlated with adiponectin levels and was negatively correlated 
with other anthropometric and biochemical parameters. 
 
Table 5. Correlation between BMI, waist circumference, cholesterol and circulating markers of 
inflammation and coagulation in obese subjects with metabolic syndrome 
 
Correlations 
Parameters    BMI  Waist  HDL  LDL  CRP  Adiponectin  Insulin  PAI-1 
BMI  Pearson 
Correlation 
1  0.474
**  -0.260
**  0.351
**  0.221
**  -0.180
**  0.160
**  0.365
** 
Sig. (2-tailed)    0.000  0.000  0.000  0.000  0.000  0.001  0.000 
Waist  Pearson 
Correlation 
0.474
**  1  -0.128
**  0.092
*  0.176
**  -0.041  0.159
**  0.307
** 
Sig. (2-tailed)  0.000    0.006  0.048  0.000  0.378  0.001  0.000 
HDL-C  Pearson 
Correlation 
-0.260
**  -0.128
**  1  -0.475
**  -0.188
**  0.184
**  -0.135
**  -0.402
** 
Sig. (2-tailed)  0.000  0.006    0.000  0.000  0.000  0.004  0.000 
LDL-C  Pearson 
Correlation 
0.351
**  0.092
*  -0.475
**  1  0.246
**  -0.225
**  0.161
**  0.501
** 
Sig. (2-tailed)  0.000  0.048  0.000    0.000  0.000  0.000  0.000 
CRP  Pearson 
Correlation 
0.221
**  0.176
**  -0.188
**  0.246
**  1  0.308
**  0.552
**  0.495
** 
Sig. (2-tailed)  0.000  0.000  0.000  0.000    0.000  0.000  0.000 
Adiponectin Pearson 
Correlation 
-0.180
**  -0.041  0.184
**  -0.225
**  0.308
**  1  0.557
**  0.001 
Sig. (2-tailed)  0.000  0.378  0.000  0.000  0.000    0.000  0.988 
Insulin  Pearson 
Correlation 
0.160
**  0.159
**  -0.135
**  0.161
**  0.552
**  0.557
**  1  0.471
** 
Sig. (2-tailed)  0.001  0.001  0.004  0.000  0.000  0.000    0.000 Functional Foods in Health and Disease 2013; 3(11):416-427                                                          Page 424 of 427 
PAI-1  Pearson 
Correlation 
0.365
**  0.307
**  -0.402
**  0.501
**  0.495
**  0.001  0.471
**  1 
Sig. (2-tailed)  0.000  0.000  0.000  0.000  0.000  0.988  0.000   
 
** Correlation is significant at p < 0.01 (2-tailed). 
* Correlation is significant at p < 0.05 (2-tailed) 
 
4. DISCUSSION 
The purpose of this study was to evaluate the effects of an extract of DG (Dyglomera®) on 
anthropometric  parameters,  blood  lipids,  and  other  variables  in  obese  patients  with  MetS. 
Because obesity results in increased visceral fat deposits that promote insulin resistance and 
inflammation through alteration of adipokine secretion, even modest reductions to weight and 
waist circumference are associated with favorable changes in serum adipocytokines [6].   
Compared to whole, ground powder [19], the extract (Dyglomera®)  induced a greater 
reduction  in  weight  (11.15  kg  vs.  7.67kg),  BMI  (4.13  kg/m
2  vs.  3.00  kg/m
2),  abdominal 
circumference (10.72 cm vs. 7.17 cm), body fat (4.43 % vs. 3.20 %), systolic blood pressure 
(24.8 mm Hg vs. 13.09 mm Hg), and  fasting blood glucose (30.7 mg/dL vs. 28.91 mg/dL). 
Weight  loss  in  overweight  and  obese  individuals  reduces  mortality  and  morbidity,  and  is 
important in the treatment of obese patients. The current data suggest that weight loss per se 
leads  to  significant  improvement  in  numerous  cardiometabolic  risk  factors.  In  particular  the 
Dyglomera®-treated subjects exhibited significant decreases in PAI-1, CRP, and fasting insulin 
levels.  In  addition,  they  showed  a  significant  increase  in  adiponectin  concentrations,  an 
adipokine whose plasma concentrations correlate positively with insulin sensitivity, and levels of 
which are lower both in obese and type 2 diabetic patients than in lean, healthy individuals [26].  
Hypoadiponectinemia is independently associated with the development of obesity-related MetS, 
as well as insulin-resistant diabetes and atherosclerosis [27], and this relationship is stronger than 
that of any other inflammatory marker [28]. Mechanisms of action of Dyglomera® may include 
antioxidant activity and inhibition of LDL oxidation [17] as well as modulation of blood glucose 
and  HbA1c  levels  [19],  all  of  which  may  have  contributed  to  the  effects  conferred  by 
Dyglomera® treatment in the present study. 
Dyslipidemia  is  a  component  of  MetS,  which  has  an    underlying  cause  of  altered 
metabolism of triglyceride-rich lipoproteins such as VLDL and IDL remnants [29,30].  Elevated 
TAG levels are also very common in both MetS and the general population [31].  The use of 
Dyglomera® by the general population could therefore have a preventive effect on dyslipidemia 
and MetS. Reducing LDL levels is generally considered a key factor in the management of 
cardiovascular risk because LDL particles are the main carriers of circulating cholesterol and 
play a key role in cholesterol transfer and metabolism [32]. The guidelines in the  Third Report 
of the National Cholesterol Education Program (Adult Treatment Panel III) (NCEP ATP III) 
focus on LDL levels as the primary target of cholesterol-lowering therapy [20].  Supplementation 
with Dyglomera® could therefore be a useful strategy to lower LDL levels.      
In summary, Dyglomera® reduces the weight and improves the atherogenic risk factors 
associated with MetS after 8 weeks of treatment. The effects in the current study, which focused 
on the extract of DG (Dyglomera®), appears to be stronger than those observed in previous Functional Foods in Health and Disease 2013; 3(11):416-427                                                          Page 425 of 427 
studies  using  whole,  ground  DG,  thus  conferring  a  superior  anti-atherogenic  capacity  on 
Dyglomera®. 
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